News
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
BioNxt announces successful completion of GMP manufacturing for sublingual Cladribine oral thin film, advancing to clinical-stage execution. Company aims to treat MS and neurodegenerative diseases -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
BioNxt Solutions Inc. secures Unitary Patent registration for sublingual cladribine oral thin film technology in Europe, enhancing commercialization prospects and partnership opportunities -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
BioNxt Solutions Inc. provides update on semaglutide ODF program and platform strategy. Focus on GLP-1 receptor agonists and peptide-based therapeutics. Potential market growth and commercial outlook discussed -
